Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-years follow-up results of the French adjuvant study group 08 trial

查看全文 作　　者：Fargeot P; Bonneterre J; RochO H; 出　　处：《J Clin Oncol》索引2004年第22卷第23期,共0页